Background: Endotherapy of postcholecystectomy bile duct stricture (PCBS) has been established as an alternative treatment to surgery. Several studies have reported conflicting results regarding the predictors of success or failure of endotherapy.
Objective: To evaluate the different cholangioscopic appearances of PCBS after endotherapy with an increasing number of plastic stents and the predictive values of these appearances for the outcome.
Design: Prospective study with a long-term follow-up.
Setting: Two academic tertiary referral centers.
Patients: Twenty consecutive patients with major bile duct injury, with a bile leak, and a PCBS who underwent therapeutic ERCP.
Interventions: Closure of the leak followed by temporary placement of multiple plastic stents for the treatment of PCBS, followed by cholangioscopy at the end of endotherapy.
Main Outcome Measurements: To analyze the predictive value of cholangioscopy, other predictors of stricture recurrence after endotherapy, and long-term clinical success.
Results: Closure of the leak was achieved in all patients. The median duration of endotherapy was 12 months (range 7-18 months). After endoscopic stenting, the PCBS was considered to be appropriately dilated in all patients. After endotherapy, 3 different findings were noted on cholangioscopy: (1) no lesion or minor defect (n = 10), (2) minor stricture with a fibrous ring (n = 6), and (3) presence of tissue hyperplasia (n = 4). During follow-up, stricture recurrence developed in 4 of 20 patients. All 4 patients were successfully retreated by an additional period of stenting and remained free of cholestasis after a median follow-up period of 44 months. By Kaplan-Meier (log-rank) and univariate analyses, the cholangioscopic pattern of tissue hyperplasia was significantly associated with stricture recurrence (P < .01).
Limitations: Small sample size.
Conclusions: Endoscopic stenting should be regarded as the primary treatment of choice because of the successful long-term outcome after 1 or more additional periods of treatment. However, the cholangioscopic pattern of tissue hyperplasia at the time of stent removal is a strong predictor of stricture recurrence, and this observation may lead to an additional period of endotherapy or other treatment modalities.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.gie.2013.07.022 | DOI Listing |
Clin J Gastroenterol
January 2025
University of Connecticut, Connecticut, USA.
Marginal ulcers are a common complication following Roux-en-Y bypass surgeries with an approximate incidence of 4.6%. The pathophysiology is complex and risk factors include smoking, nonsteroidal anti-inflammatory drugs (NSAIDs) use, Helicobacter pylori infection, and a larger pouch size.
View Article and Find Full Text PDFIJU Case Rep
January 2025
Department of Urology Bendigo Health Bendigo Victoria Australia.
Introduction: This report describes late erosion of an Adjustable Transobturator Male System device which was inserted for post-prostatectomy incontinence. The Adjustable Transobturator Male System device eroded the bulbar urethra 5 years post insertion, despite initial improvement of symptoms.
Case Presentation: Following an open radical retropubic prostatectomy, a 64 year-old male patient developed post-prostatectomy incontinence.
Introduction: Ureteral stricture disease (UTSD) poses significant challenges in reconstructive urology, with recent advances highlighting disparities in healthcare outcomes based on race and ethnicity. This study investigates the impact of race and ethnicity on clinical outcomes following ureteral reconstruction.
Methods: We conducted a single-centre prospective analysis of 233 patients who underwent ureteral reconstruction for UTSD from 2014 to 2023.
Cureus
November 2024
Medicine and Surgery, University Hospitals Coventry and Warwickshire, Coventry, GBR.
The Optilume drug-coated balloon (DCB) (North Plymouth, USA) is a novel treatment option for urethral stricture disease that combines mechanical dilation with localized delivery of paclitaxel, an antiproliferative drug aimed at reducing recurrence rates by inhibiting scar tissue formation. This systematic review and meta-analysis, conducted using studies published in the last 10 years up to November 2024, assessed the efficacy and safety of Optilume DCB across seven studies involving 457 patients. Key outcomes included significant reductions in symptom scores, as measured by the International Prostate Symptom Score (IPSS), and improvements in urinary flow rates (QMax).
View Article and Find Full Text PDFUrology
December 2024
King's College London, London, United Kingdom; Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!